N015477 N0 Ruling Active

The tariff classification of Pramipexole Dihydrochloride (CAS-191217-81-9), and Meropenem (CAS-119478-56-7) imported in bulk form, from Italy

Issued August 23, 2007 by U.S. Customs and Border Protection.

Tariff classification

HTS codes: 2934.20.4000, 2941.90.5000

Headings: 2934, 2941

Product description

The first product, Pramipexole Dihydrochloride, is indicated for the treatment of Parkinson’s disease. The second product, Meropenem is a synthetic, broad spectrum, carbapenem antibiotic and is used for the treatment of various bacterial infections.

CBP rationale

The applicable subheading for the Pramipexole Dihydrochloride, imported in bulk form, will be 2934.20.4000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for "Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds: Compounds containing in the structure a benzothiazole ring-system (whether or not hydrogenated), not further fused: Other: Other: Products described in additional U. The applicable subheading for the Meropenem, imported in bulk form, will be 2941.90.5000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Antibiotics: Other: Other: Other.

Full text

N015477 August 23, 2007 CLA-2-29:RR:NC:2:238 CATEGORY: Classification TARIFF NO.: 2934.20.4000; 2941.90.5000 Ms. Laura Mannisto Interchem Corporation 120 Route 17 North P.O. Box 1579 Paramus, NJ 07652-1579 RE: The tariff classification of Pramipexole Dihydrochloride (CAS-191217-81-9), and Meropenem (CAS-119478-56-7) imported in bulk form, from Italy Dear Ms. Mannisto: In your letter dated August 2, 2007, you requested a tariff classification ruling. The first product, Pramipexole Dihydrochloride, is indicated for the treatment of Parkinson’s disease. The second product, Meropenem is a synthetic, broad spectrum, carbapenem antibiotic and is used for the treatment of various bacterial infections. The applicable subheading for the Pramipexole Dihydrochloride, imported in bulk form, will be 2934.20.4000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for "Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds: Compounds containing in the structure a benzothiazole ring-system (whether or not hydrogenated), not further fused: Other: Other: Products described in additional U.S. note 3 to section VI." Pursuant to General Note 13, HTSUS, the rate of duty will be free. The applicable subheading for the Meropenem, imported in bulk form, will be 2941.90.5000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Antibiotics: Other: Other: Other." The rate of duty will be free. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at http://www.usitc.gov/tata/hts/. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Harvey Kuperstein at 646-733-3033. Sincerely, Robert B. Swierupski Director, National Commodity Specialist Division

View original on CBP CROSS →

More rulings on the same tariff codes

Searching CBP rulings the smart way

TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.

Book a demo →